Valuation: Alkermes plc

Market Cap 8.66B 7.57B 6.98B 6.45B 12.24B 826B 12.45B 83.45B 32.77B 407B 32.5B 31.8B 1,398B P/E 2026 *
-135x
P/E 2027 * 88.3x
Enterprise Value 9.62B 8.41B 7.76B 7.17B 13.6B 917B 13.83B 92.72B 36.41B 452B 36.11B 35.33B 1,554B EV / Sales 2026 *
5.32x
EV / Sales 2027 * 4.95x
Free-Float
89.39%
Yield 2026 *
-
Yield 2027 * -
1 day-3.42%
1 week-4.84%
Current month-0.87%
1 month+18.48%
3 months+55.70%
6 months+75.12%
Current year+85.63%
1 week 51.86
Extreme 51.86
55.67
1 month 43.34
Extreme 43.34
55.67
Current year 27
Extreme 27
55.67
1 year 25.16
Extreme 25.165
55.67
3 years 22.01
Extreme 22.01
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 64 31/01/1991
Director of Finance/CFO 53 14/09/2025
Chief Tech/Sci/R&D Officer 58 29/05/2017
Director TitleAgeSince
Chairman 64 31/08/2011
Director/Board Member 74 25/05/2016
Director/Board Member 63 29/03/2018
Date Insider Type Main position Quantity % Market Cap.
07-05Sell

Compliance Officer

-2,034 0.0012%
06-30Fiscal year

Chief Technology Officer

19,000 0.0114%
06-11Sell

Director

-2,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
-3.42%-4.84%+70.52%+75.24% 8.66B
+0.58%+2.06%+2.92%+10.86% 50.73B
-2.22%-1.25%+385.40%+586.81% 39.73B
-0.54%+0.39%+25.57%-5.28% 34.69B
-1.36%+0.35%+17.88%+55.14% 33.21B
+1.21%-4.58%+3.00%+35.46% 26.76B
-1.81%-1.48% - - 16.8B
+0.51%-3.47%+63.97%+122.60% 15.37B
+0.23%-0.58%+13.76%+21.11% 13.78B
-0.62%-3.09%+10.29%-31.35% 12.85B
Average -0.74%-1.23%+65.92%+96.73% 25.26B
Weighted average by Cap. -0.58%-0.39%+80.32%+122.52%

Financials

2026 *2027 *
Net sales 1.81B 1.58B 1.46B 1.35B 2.56B 173B 2.6B 17.44B 6.85B 85.01B 6.79B 6.65B 292B 1.89B 1.65B 1.53B 1.41B 2.67B 180B 2.72B 18.23B 7.16B 88.83B 7.1B 6.94B 305B
Net income -64.63M -56.53M -52.15M -48.16M -91.39M -6.16B -92.92M -623M -245M -3.04B -243M -237M -10.44B 101M 87.93M 81.1M 74.91M 142M 9.59B 145M 969M 381M 4.72B 377M 369M 16.24B
Net Debt 961M 841M 776M 716M 1.36B 91.68B 1.38B 9.27B 3.64B 45.16B 3.61B 3.53B 155B 702M 614M 566M 523M 992M 66.91B 1.01B 6.76B 2.66B 32.96B 2.63B 2.58B 113B
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
10/07/26 US$51.94 -3.42% 1,691,454
09/07/26 US$53.78 -0.94% 1,630,543
08/07/26 US$54.29 -1.68% 1,706,011
07/07/26 US$55.22 +0.15% 1,719,310
06/07/26 US$55.14 +1.03% 1,747,218
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
51.94USD
Average target price
50.56USD
Spread / Average Target
-2.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock